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Abstract
Growth hormone (GH) is a well established participant in several complex physiological processes including growth, diffe-
rentiation, and metabolism. Recombinant human GH is a drug that has been approved for use for several clinical condi-
tions where the action of GH is diminished or completely lacking. Thus there is considerable interest in developing novel
drugs that modify the function of GH. Only in the last several decades have the detailed structural features of GH along
with its interaction with its receptor been elucidated. In this review we summarise the basic structural and functional
properties of GH, its receptor and their interaction. In addition, we discuss the discovery and development of an effective
GH receptor antagonist, pegvisomant, and summarise potential therapeutic uses of this drug.
(Pol J Endocrinol 2007; 58 (4): 322–329)
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Streszczenie
Hormon wzrostu (GH, growth hormone) uczestniczy w wielu fizjologicznych procesach dotyczących wzrastania, różnico-
wania i metabolizmu. Leczenie rekombinowanym ludzkim GH jest akceptowane w wielu schorzeniach wiążących się
z całkowitym brakiem lub zmniejszeniem działania GH. Wynika stąd znaczne zainteresowanie rozwojem nowych leków
mogących modyfikować czynność GH. Dopiero niedawno wyjaśniono dokładną strukturę GH i jego interakcje z recepto-
rem. W niniejszej pracy autorzy podsumowują wiedzę dotyczącą podstawowej budowy GH, jego receptora i interakcji
między nimi. Ponadto, omówiono odkrycie i rozwój skutecznego antagonisty receptora GH, pegvisomantu i przedstawio-
no potencjalne możliwości zastosowania terapeutycznego tego leku.
(Endokrynol Pol 2007; 58 (4): 322–329)
Słowa kluczowe: hormon wzrostu, receptor hormonu wzrostu, antagonista receptora hormonu wzrostu
Introduction
The functions of growth hormone (GH) are pervasive,
having a direct or indirect impact on most tissues in the
body. To exert its biological effect, GH interacts with
specific GH receptors (GHRs) on the surface of target
tissues. GHRs have been detected in a variety of tissues,
including liver, adipose tissue, muscle, lymphocytes,
prostate, kidney, placenta, heart, brain and mammary
gland [1–5]. Binding of GH to GHRs on target tissues
activates proteins involved in the Janus kinase/signal
transducer and activator of transcription (JAK-STAT)
signal transduction pathway, as well as other pathways
[6]. In addition to having a direct impact on target tis-
sues, GH stimulates the synthesis and release of insu-
lin-like growth factor-1 (IGF-1). Since IGF-1 has many
distinct metabolic effects, GH has the ability to alter tis-
sue function, both directly and indirectly, via IGF-1 pro-
duction. Thus GH, along with IGF-1, is considered
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to have dual effects on target tissues [7, 8] with the ini-
tiator of this cascade being the interaction of GH with
the GHR.
Disorders in growth, either via GH deficiency (GHD)
or by production of elevated levels of GH such as in
acromegalic individuals, have resulted in a variety of
treatment modalities. For deficiency states rhGH has
been approved by the FDA for treatment of several
growth retardation conditions in children including
GHD, Turner syndrome, chronic renal disease, Prader-
Willi syndrome and intrauterine growth retardation and
for children born small for gestational age (SAGE) or
with idiopathic short stature. In adults, rhGH has been
approved for GHD associated with a history of hypo-
thalamic and/or pituitary disorders and, more recently,
for human immunodeficiency virus (HIV)-associated
wasting. The guidelines for rhGH use in children and
adults have been thoroughly reviewed elsewhere in more
detail [9–11]. Recently, recombinant IGF-1 has been ap-
proved for children resistant or insensitive to GH treat-
ment [12]. For conditions of elevated GH (gigantism and
acromegaly) drugs that lower GH secretion (somato-
statin analogues) or inhibit GH activity (GH antagoni-
sts) are currently used. Thus by altering the GH/GHR
interaction both GH and IGF-1 activities will be affec-
ted. In the future the ability to uncouple the action of
GH from that of IGF-1 will certainly result in the disco-
very of new therapeutic targets.
GH and GHR structure
The primary sequence of GH from many species, as well
as the crystal structure of both porcine (p) and human
(h) GH, has provided significant insight as to the struc-
turally significant regions of this hormone. Although
somewhat variable according to the species, the main
secreted form of GH is composed of ~191 amino acids.
Analysis of the three-dimensional structure of pGH [13]
and hGH [14] has revealed that both are globular pro-
teins which contain four highly conserved cysteine re-
sidues. These cysteine residues form both a large and
a small disulfide bridge with the large bridge being im-
portant for GH activity [15]. Approximately one half of
the amino acid residues in GH reside in four distinct
alpha helices. These four anti-parallel helices connect
in an “up-up-down-down” pattern with the core of the
four-helical bundle consisting of mostly hydrophobic
residues, which presumably function to hold the heli-
ces in a specific packed configuration [14]. Relevant to
this review, a tryptic peptide of GH containing helix
3 was previously shown to have significant growth-pro-
moting activity [16], although this was not documen-
ted to be critical for GHR recognition.
The GHR belongs to the cytokine receptor superfa-
mily, which also includes the receptors for granulocy-
te-colony stimulating factor, leptin and prolactin as well
as other cytokines [17]. There are common features and
motifs among this receptor family. In particular, recep-
tor family members contain several specific disulfide
bonded Cys residues and a distinct WSXWS-like (Trp,
Ser, any amino acid, Trp and Ser) motif near the cell
membrane. The GHR is composed of approximately
620 amino acids. The N-terminus contains the extracel-
lular hormone-binding region (~245 amino acids), fol-
lowed by the 24 amino acid hydrophobic transmem-
brane region and the C-terminal domain (~350 amino
acids), which contains motifs important in intracellular
signalling [18]. On the basis of analysis of the crystal
structure of human GHR, the extracellular region con-
tains two distinct yet similarly designed domains (ter-
med 1 and 2), each composed of seven beta strands di-
vided into two anti-parallel beta sheets [14].
Interaction of GH with the GHR
The sensitivity of a tissue to GH is partly dependent on
the number of cell-surface GHRs in that tissue. The stoi-
chometry of the ligand:receptor complex is 1:2, based
on a number of biophysical methods and later confir-
med through X-ray crystallography data [14, 19]. Thus
a single GH molecule interacts with a homodimer of
the GHR. Several studies have revealed that GHR exi-
sts as a preformed homodimer [20–22], which under-
goes a conformational change in the intracellular signal-
ling region of the receptor, initiating the signalling ca-
scade [23]. This account of the heterotrimeric GH:GHR
interaction is depicted in Figure 1.
The regions of GH responsible for receptor binding
have been exhaustively studied [24–29]. These studies
identified a patch of three regions of GH that come into
close proximity in the three-dimensional structure,
which are responsible for the high affinity binding of
GH to its receptor [24, 25]. These three regions of GH,
collectively referred to as Site 1, include the N-terminal
portion of helix 1, a portion of the connection between
helices 1 and 2, and the C terminal portion of helix 4.
Yet, GH forms a hGH:GHR2 complex and is an asym-
metric protein, suggesting that an additional site wi-
thin GH (first suggested by Chen et al [30]) was respon-
sible for binding the second GHR monomer. This addi-
tional site was later found in helix 3 of GH and is called
Site 2. Because two physically separate sites of a single
GH protein are responsible for binding to the GHR, it
may not be surprising that Site 1 of GH interacts with
higher affinity to GHR than Site 2 [14]. Described sequen-
tially, Site 1 of GH is thought to interact with higher
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affinity to the first GHR monomer, followed by the bin-
ding of Site 2 of GH to the second GHR monomer with
lower affinity.
Discovery of the GH antagonist
Detailed focus was placed on the 3rd a-helix of GH due
to the growth-promoting abilities [16, 30, 31] observed
to be specific to that helix. Mutations at 3 amino acid
sites within bovine (b) GH helix 3 were engineered to
provide an amphipathic formation hypothesised to fur-
ther enhance the growth-promoting activity of this he-
lix. Specifically, the substitutions were Glu-117 to Leu,
Gly-119 to Arg, and Ala-122 to Asp in bGH. This GH
analogue bound to the GHR’s with the same affinity as
wild-type GH [30]. Surprisingly, this GH analogue an-
tagonised the action of wild-type GH in transgenic mice,
resulting in a dwarf phenotype [30–32]. This result re-
presents the first discovery of a GH antagonist. Further
investigation of each individual substitution revealed
that the specific replacement of Gly-119 with Arg pro-
moted the GH antagonist effect [29]. This single Gly-
119 amino acid substitution is sufficient to promote
a dwarf phenotype in mice transgenic for the GH anta-
gonist (Fig. 2) [31].
Interestingly, the Gly at this position is conserved
in all members of the GH family. The GH antagonist is
able to bind with high affinity to the preformed GHR
dimer while blocking subsequent signal transduction
(Fig. 3) [30, 31, 33]. Gly’s side chain is made up of a sin-
gle hydrogen atom, which, in the context of other ami-
no acids in the vicinity, creates a cleft in a region of the
3rd helix (Fig. 4). The substitution of this Gly with
an amino acid containing a bulky side chain fills this
gap, which ultimately generates the GH antagonist [29].
It is important to note that these types of GH antago-
nist bind to the GHR with affinities similar to wild-type
GH and do not inhibit GHR dimerisation but perturb
proper or functional GHR dimerisation.
Figure 1. Model for the formation and signal transduction of the
heterotrimeric complex between GH and 2GHR. A. The preformed
dimer of GHR is shown embedded in the lipid bilayer and GH is
in the extracellular space. B. Site 1 (within GH) binds with high
affinity to a monomer of the preformed GHR dimer. C. Site 2 (within
GH) subsequently binds the second GHR, resulting in signal
transduction. (Reprinted with permission from Cold Spring
Laboratory Press [91]
Rycina 1. Schemat powstawania i przekazywania sygnału
w obrębie kompleksu heterotrimerycznego między cząsteczkami GH
i 2GHR. A. Wbudowany w dwuwarstwę lipidową preformowany
dimer GHR; GH znajduje się w przestrzeni zewnątrzkomórkowej.
B. Miejsce 1. (w obrębie GH) wiąże się z dużym powinowactwem
do jednego z monomerów proformowanego dimeru GHR.
C. Miejsce 2. (w obrębie GH) wiąże się następnie z drugim
monomerem dimeru GHR, co powoduje przewodzenie sygnału
Figure 2. Photograph showing size comparison of control (bottom)
and GH antagonist transgenic mice (top). Shown are 6-week old
male mice
Rycina 2. Na fotografii przedstawiono różnice w wielkości między
kontrolną (u dołu) i transgeniczną myszą po zadziałaniu antagonistów
GH (u góry). Przedstawione myszy to 6-tygodniowe osobniki
męskie
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Development of a long-acting,
effective GH antagonist
Owing to GH’s relatively short half life (30 minutes),
it has proved challenging to create a GH antagonist mo-
lecule that was an effective therapeutic agent. In order
to counteract kidney excretion of low molecular weight
GH, the addition of polyethylene glycol (PEG) was used
to significantly increase the molecular mass of the
protein [34]. This technology was adapted for the GH
antagonist. The PEG addition decreased the affinity of
the GH antagonist for its receptor but still proved an
effective antagonist because the serum half-life was im-
proved [21]. Furthermore, in an attempt to improve the
affinity of the pegylated GH antagonist for its receptor,
8 amino acid substitutions were generated at Site 1, each
of which had previously been shown to improve the
affinity for GH binding protein [35]. This 8 amino acid
substituted and pegylated antagonist (containing lysi-
ne at Gly 120) had improved binding affinity for mem-
brane receptors as compared to the pegylated Gly 120K
antagonist, resulting in a more effective molecule [21].
This pegylated GH antagonist has been termed
pegvisomant and the approved marketed name is
Somavert ® (pegvisomant for injection). Many papers
have documented the clinical efficacy of pegvisomant and
these will not be further reviewed here. However, readers
should visit the following papers and reviews for specific
details concerning the many clinical trials [36–45].
Pegvisomant and diabetes
Although it has been known for many decades that GH
inhibits insulin’s action[46–49], the mechanism respon-
sible for this effect has remained elusive. Recent data
have started to illuminate possible mechanisms. For
example, a recent link between a specific GHR poly-
Figure 3. Model representing the interaction of the GH antagonist
with the receptor. A. A preformed dimer of GHR is shown embedded
in the lipid bilayer with the GH antagonist in the extracellular
space. B. Site 1 within the GH antagonist binds with high affinity
to one monomer of the preformed GHR dimer. C. Improper binding
at Site 2 within the GH antagonist blocks subsequent intracellular
signal transduction. (Reprinted with permission from Cold Spring
Harbor Laboratory Press [91])
Rycina 3. Na schemacie przedstawiono oddziaływanie między
anta-gonistą GH a receptorem. A. Wbudowany w dwuwarstwę
lipidową preformowany dimer GHR; antagonista GH znajduje
się w przestrzeni zewnątrzkomórkowej. B. Miejsce 1. (w obrębie
GH) wiąże się z dużym powinowactwem do jednego z monomerów
proformowanego dimeru GHR. C. Nieprawidłowe wiązanie
miejsca 2. (w obrębie cząsteczki antagonisty GH) do drugiego
monomeru GHR blokuje późniejsze wewnątrzkomórkowe
przewodzenie sygnału
Figure 4. Partial space filling model of the third alpha helix of
bGH and bGH-G119R. A. Structural representation of the third
alpha helix when the glycine is substituted with an arginine.
B. Structural representation of the wild-type helix. The position
of the cleft is indicated. (Reprinted, with permission, (38) [Ó The
Endocrine Society])
Rycina 4. Częściowy model przestrzenny trzeciej alfa helisy bGH
i bGH-G119R. A. Struktura trzeciej alfa helisy po podstawieniu
glicyny argininą. B. Struktura helisy typu dzikiego. Zaznaczono
pozycję szczeliny
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morphism and resistance to Type 2 diabetes (T2DM)
has been presented [50]. Furthermore, mice transgenic
for bGH are insulin resistant, while mice that lack GH
signalling are insulin sensitive despite their obesity [51–53].
In terms of intracellular signalling events that account
for GH-induced insulin resistance, disruption of p85al-
pha, a subunit of PI 3-kinase, will increase insulin sen-
sitivity, while elevated p85alpha levels are associa-
ted with insulin resistance [54–57]. A recent study by
del Rincon et al. reports that GH up-regulates expres-
sion of p85alpha in white adipose tissue and suggests
this may be responsible for alterations in insulin sensi-
tivity seen in mouse models of altered GH action [58].
A similar situation also occurs in muscle [56]. Thus the
diabetogenic effect of GH may be due to “cross-talk”
between the GH and insulin signalling pathways.
The established impact of GH on insulin sensitivity
led researchers to monitor parameters of insulin action
in human subjects given pegvisomant. Healthy subjects
given pegvisomant for 7 days did not show altered glu-
cose tolerance or stimulated insulin secretion [59]. As
pegvisomant began to be used to treat acromegaly,
a disease often accompanied by insulin resistance and
diabetes, clinicians were able to examine the effect of
this drug on insulin sensitivity and other measures of
diabetes. In 2002 Rose and Clemmons reported that tre-
atment with pegvisomant lowered fasting insulin, glu-
cose and haemoglobin A(1)C levels in patients with acro-
megaly [60]. Later studies have further confirmed an
improvement in insulin sensitivity following pegviso-
mant treatment of patients with acromegaly [61–63].
Clearly, pegvisomant can improve insulin and glucose
levels in patients with acromegaly, but what about patients
with other insulin-related conditions? Williams et al.
treated young, Type 1 diabetic adults with 5 or
10 mg/day of pegvisomant for 3 weeks [64]. No chan-
ges in insulin sensitivity under hyperinsulinaemic eu-
glycaemic clamp conditions were observed; however,
both doses of pegvisomant decreased the amount
of insulin required overnight to maintain euglycaemia.
Thus although there has been limited research to date,
pegvisomant shows promise for treating not only acro-
megalics with insulin resistance but also young adult
patients with Type 1 diabetes. Further research is requ-
ired to determine if pegvisomant treatment might be-
nefit patients with type 2 diabetes as well.
Pegvisomant and nephropathy
Long and short term renal changes can be caused by
GH and IGF-1. Transgenic mice expressing GH antago-
nist are dwarf and have reduced circulating IGF-1 le-
vels [30, 32]. When GH antagonist mice are made dia-
betic, they are protected from renal damage [65]. In
addition, treatment of control and diabetic mice with
GH antagonist protects them from renal damage [66, 67]
and prevents compensatory renal growth in uni-neph-
rectomised mice [68]. The mechanism in which GH an-
tagonist protects the kidney has not been determined,
but studies point to several possibilities. When exogeno-
us GH antagonist is administered in increasing doses to
adult female Balb/C mice, there is a dose-dependent de-
crease in hepatic and serum IGF-1 levels, no effect on
hepatic or renal IGFBP-1 and 3 levels, and an increase in
hepatic and circulatory IGFBP-4 levels [69]. In effect, this
would create a significant decrease in IGF-1 bioavailabi-
lity. Additionally, variable concentrations of pegvisomant
have a significant impact on the GHR/GHRBP gene trans-
cription in stable cell lines of T-SV40 immortalised glo-
merular mesangial cells [70, 71]. Interestingly, GH anta-
gonist has been reported to inhibit GHR/GHRBP gene
transcription directly at the cellular level in human me-
sangial cells at all concentrations of pegvisomant tested
[72]. Collectively, this data indicates that pegvisomant
administration may influence kidney function.
Pegvisomant and retinopathy
The role of GH in the development of retinopathy was
first described after ablation of the pituitary gland re-
sulted in reduction of the disease [73, 74]. This result,
coupled with the fact that diabetic dwarfs do not deve-
lop retinopathy [75], suggests that the use of GH anta-
gonists for the treatment of diabetic retinopathy may
be beneficial. Furthermore, results using mice expres-
sing a GH antagonist to study non-diabetic ischemia-
induced retinal neovascularisation showed an inhibi-
tion of neovascularisation despite elevated levels of
vascular endothelial growth factor receptor [76]. Pegvi-
somant treatment of diabetic patients with severe reti-
nopathy ensued. In this 12-week study, where type 1
and type 2 diabetic patients were treated daily with
pegvisomant, no regression of retinopathy was seen
[77]. However, considering the short length of the stu-
dy as well as the advanced retinopathy of the subjects,
further studies are warranted.
Pegvisomant and cardiovascular disease
Acromegaly has been shown to be associated with an in-
creased cardiovascular risk. Thus it is not surprising that
CRP (C-reactive protein) levels, a common marker for car-
diovascular risk, were found to be lower with the admini-
stration of pegvisomant in humans [78]. Since pegvisomant
blocks GHR activation and decreases IGF-1 production, the
effects observed on CRP could be mediated both by the
decrease in IGF-1 and the direct effect of GHR blockade.
GH antagonist treatment in patients with acromegaly is
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also known to induce a reduction in diastolic blood pres-
sure in hypertension and improve glucose metabolism [62].
A recent study by Pivonello et al. also showed that pegvi-
somant can reverse left ventricle hypertrophy and pro-
gressively improve left ventricular diastolic and systolic
performance in acromegalics [79]. Thus long term treat-
ment with pegvisomant has positive effects on cardiova-
scular function and may prevent the development or pro-
gression of cardiac insufficiency, at least for acromegalics.
Pegvisomant and cancer
The IGF-1/GH axis has been implicated in contributing
to the growth and formation of many different cancers
[80, 81]. IGF-1 has been shown to be a growth factor for
numerous types of cancer and neoplastic growth [82].
Additional studies have also shown that some neoplasms
are also capable of producing autocrine and/or paracrine
IGF-1 [82]. Transfection of MCF-7 cells with the hGH gene
showed that these cells synthesised and secreted hGH into
the media, and these cells were found to have higher le-
vels of STAT5-mediated transcriptional activation than
controls [83]. The disruption of excess GH stimulation and
therefore reduction in IGF-1 levels may therefore be use-
ful in the treatment of numerous cancers.
Multiple studies using both animals and humans
have attempted to show the beneficial use of GH anta-
gonist to prevent or slow the growth of various tumo-
urs. GH antagonist mice were found to have lower IGF-
1 levels and a decreased mammary tumour incidence
in relation to litter-mate controls when exposed to
a chemical carcinogen [84]. Additional studies using
GHR/-and C3(1)/Tag mouse models showed an inhibi-
tion of oestrogen-independent mammary carcinogene-
sis [85]. Recently a study using the spontaneous dwarf
rat (an animal known to have lower levels of GH and
IGF-1) injected with GH showed that these animals
were more vulnerable to mammary carcinogenesis with
increasing levels of circulating IGF-1 and GH [86]. Pe-
gvisomant administration to virgin female mice caused
a 70–80% reduction in serum IGF-1 levels and a 30%
reduction in the volume of MCF-7 xenografts [87]. In
mice the growth of human meningioma xenografts si-
gnificantly decreased following pegvisomant treatment,
and in some cases tumour regression was observed [88].
Additional studies xenografting human colorectal can-
cer lines into female nude mice with subsequent pegvi-
somant treatment reported a 39% reduction in tumour
volume with a reduction in both IGF-1 and IGFBP-3
levels [89]. Studies involving GHR disrupted and Tag
mice suggest that the disruption of GH signalling may
also reduce prostate carcinogenesis [90]. These results
indicate a potential therapeutic use of pegvisomant in
the prevention and treatment of certain cancers.
Conclusion
Since the initial discovery of a growth hormone anta-
gonist [30] both basic and clinical studies have advan-
ced. In terms of human use, the growth hormone anta-
gonist Somavert® (pegvisomant for injection) has been
approved for lowering IGF-1 levels in acromegalic in-
dividuals. Further studies are likely to provide insight
into its therapeutic potential for the treatment of diabe-
tes, diabetic complications and cancer indications. Fi-
nally, the growth hormone antagonist is now a com-
monly used reagent that specifically antagonises the
effects of growth hormone in many basic research sce-
narios. In the future, the growth hormone antagonist
will also assist researchers in uncoupling the biological
effects of growth hormone from those of IGF-1.
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